SEC Form 4		
FORM	4	

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL

OMB Number:	3235-0287
Estimated average bu	ırden
hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* GRYSKA DAVID W				er Name and Ticker BIOPHARM			5. Relationship of Reporting Person(s) to Issuer (Check all applicable)					
<u>UKI SKA I</u>	<u>DAVID w</u>					L .	X	Director	10% C			
(Last) 932 SOUTHW	(First) VOOD BLVD.	(Middle)	3. Date 11/18/	of Earliest Transac 2020	tion (Month/D	ay/Year)		Officer (give title Other (s below) below)				
(Street)			4. If Am	endment, Date of C	Driginal Filed (Month/Day/Year)	6. Indiv Line)	ndividual or Joint/Group Filing (Check Applica				
INCLINE VILLAGE	NV	89451					X	Form filed by One Form filed by Mo Person				
(City)	(State)	(Zip)										
		Table I - Nor	n-Derivative So	ecurities Acqu	lired, Disp	osed of, or Benefi	cially	Owned				
1. Title of Securi	ity (Instr. 3)		2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A Disposed Of (D) (Instr. 3, 5)		5. Amount of Securities Beneficially Owned Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership		

Code V Amount (A) or (D) Price Transaction(s) (Inst. 3 and 4) (Inst. 4) Common stock 11/18/2020 M 60,000 A \$1.64 155,337 D Image: Common stock					Reported	(I) (Instr. 4)	(Instr. 4)				
Common stock 11/18/2020 M 60,000 A \$1.64 155,337 D				Code	v	Amount	(A) or (D)	Price	Transaction(s)		(1150.4)
	Common stock	11/18/2020		М		60,000	Α	\$1.64	155,337	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

			(0)	. ,				, . F			,								
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code (8)		of Deri Sec Acq (A) o Disp of (I	umber vative urities uired or oosed D) (Instr. and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		Expiration Date		Expiration Date		piration Date of Securities		8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares								
Stock Option (right to buy)	\$1.64 ⁽¹⁾	11/18/2020		М			60,000	11/05/2020	06/19/2029	Common stock	60,000	\$ 1.64	66,050	D					

Explanation of Responses:

1. On May 21, 2020, the Company completed the distribution to its stockholders of its shares of common stock in Evofem Biosciences, Inc., which resulted in a \$0.58 reduction to the exercise price of the stock option at such time pursuant to the Company's wind-down retention plan. On October 1, 2020, the Company completed the distribution to its stockholders of its shares of common stock in LENSAR, Inc., which resulted in a \$0.78 reduction to the exercise price of the stock option at such time pursuant to the Company's wind-down retention plan.

Remarks:

<u>/s/ Nathan N. Kryszak,</u> <u>Attorney-in-Fact for David W.</u> <u>11/20/2020</u> <u>Gryska</u>

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.